8-K: Cyclo Therapeutics Stockholders Approve Merger with Rafael Holdings

Cyclo Therapeutics stockholders voted to approve the merger agreement with Rafael Holdings at a special meeting held on March 20, 2025.

Summary

• Cyclo Therapeutics, Inc. held a special meeting of stockholders on March 20, 2025, to vote on a merger proposal with Rafael Holdings, Inc.
• The merger agreement, dated August 21, 2024, and amended on December 18, 2024, and February 4, 2025, involves Cyclo Therapeutics becoming a wholly-owned subsidiary of Rafael Holdings through a merger with Tandem Therapeutics, Inc. and Tandem Therapeutics, LLC, both subsidiaries of Rafael.
• Stockholders also voted on a proposal to adjourn the meeting if necessary to solicit additional proxies.
• As of the record date, February 13, 2025, there were 32,919,184 shares of Cyclo Therapeutics common stock outstanding.
• A quorum of 57.6% of outstanding shares (18,953,123 shares) was present at the meeting.
• The Merger Proposal was approved with 18,548,536 votes for, 396,733 against, and 7,860 abstentions.
• The Adjournment proposal was also approved, but rendered moot due to the approval of the Merger Proposal.
• The merger is expected to close on March 25, 2025, subject to customary closing conditions.

Sentiment

Score: 7

Explanation: The document is factual and reports the successful vote for a merger, which is generally a positive event for the companies involved. The sentiment is moderately positive as it indicates progress towards a strategic goal.

Positives

• The merger proposal was approved by a significant majority of the stockholders.
• The merger is expected to close soon, providing clarity and potentially unlocking value for shareholders of Rafael Holdings.

Risks

• The merger is subject to customary closing conditions, which if not met, could delay or prevent the completion of the transaction.
• The integration of Cyclo Therapeutics into Rafael Holdings could present challenges.

Future Outlook

Subject to the satisfaction or waiver of customary closing conditions set forth in the Merger Agreement, the Merger is expected to close on March 25, 2025.

Management Comments

• N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, signed the report on behalf of the company.

Industry Context

Mergers and acquisitions are common in the pharmaceutical and biotechnology industries as companies seek to expand their pipelines, acquire new technologies, or achieve synergies.

Comparison to Industry Standards

• It is difficult to compare this merger directly to industry standards without knowing the specific financial terms and strategic rationale behind the deal.
• However, mergers of this nature are often compared to deals involving companies with similar market capitalizations, product pipelines, and strategic goals.
• Comparable companies and projects would need to be assessed based on the specifics of Cyclo Therapeutics' and Rafael Holdings' businesses.

Stakeholder Impact

• Shareholders of Cyclo Therapeutics will have their shares converted into consideration as defined in the merger agreement.
• Employees of Cyclo Therapeutics will become part of Rafael Holdings.
• The merger could impact customers and suppliers of Cyclo Therapeutics depending on the integration strategy of Rafael Holdings.
• Creditors of Cyclo Therapeutics will be impacted by the change in ownership.

Next Steps

• Satisfaction or waiver of customary closing conditions.
• Closing of the merger transaction on or around March 25, 2025.
• Integration of Cyclo Therapeutics into Rafael Holdings.

Key Dates

Keywords

Merger, Rafael Holdings, Cyclo Therapeutics, Stockholders, Agreement, Subsidiary